8-K: Journey Medical Reports Q2 2024 Results: Revenue Up Sequentially, DFD-29 Awaits FDA Decision

Journey Medical Corporation announced a 14% sequential increase in revenue for the second quarter of 2024, along with positive adjusted EBITDA and progress on its DFD-29 drug application.

Summary

• Journey Medical Corporation reported a total revenue of $14.9 million for the second quarter of 2024, which is a 14% increase compared to the first quarter of 2024.
• However, the revenue decreased by 12% compared to the second quarter of 2023, primarily due to the timing of customer orders for Qbrexza, generic competition for Targadox, and the discontinuation of Ximino.
• The company's net loss significantly improved, decreasing from $8.4 million in Q2 2023 to $3.4 million in Q2 2024.
• Adjusted EBITDA was positive at $0.3 million for the second quarter of 2024, compared to a negative $0.6 million in the same period last year.
• Research and development costs decreased to $0.9 million in Q2 2024 from $1.8 million in Q2 2023 due to the completion of clinical trials for DFD-29.
• Selling, general, and administrative expenses also decreased to $10.3 million in Q2 2024 from $12.1 million in Q2 2023, reflecting the company's cost reduction efforts.
• The company had $23.9 million in cash and cash equivalents as of June 30, 2024.
• The FDA has set a PDUFA goal date of November 4, 2024, for the company's DFD-29 drug application for rosacea treatment.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the sequential revenue growth, positive adjusted EBITDA, and progress on DFD-29. However, the year-over-year revenue decline and ongoing net loss temper the overall optimism.

Positives

• The company experienced a 14% sequential increase in revenue from the first quarter of 2024.
• Journey Medical achieved positive adjusted EBITDA in the second quarter of 2024.
• The net loss was significantly reduced by $5.0 million compared to the same quarter last year.
• The company successfully reduced its operating expenses through cost-cutting measures.
• The FDA accepted the NDA filing for DFD-29 with a PDUFA goal date set for November 4, 2024.
• The company strengthened its leadership team with the appointment of a permanent CFO and a new board member.

Negatives

• Total revenue decreased by 12% compared to the second quarter of 2023.
• The company still reported a net loss of $3.4 million for the second quarter of 2024.
• The decrease in revenue compared to the prior year was attributed to the timing of customer orders, generic competition, and the discontinuation of a product.

Risks

• The company's products are subject to regulatory approvals and clinical testing, which may not always be successful.
• A substantial portion of sales comes from products that may face generic competition.
• The company operates in a heavily regulated industry, and future legislation could impact operations.
• The company's revenue is dependent on the sales of dermatology products, and any setback could impair results.
• Competition from other companies could limit the commercial opportunity and profitability of their products.
• The company relies on third parties for several aspects of its operations.
• The company's success depends on the development and approval of DFD-29 and other future products.
• Clinical trials may not demonstrate the safety and efficacy of their product candidates.
• The company faces risks related to intellectual property protection and cybersecurity.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company may need to raise additional capital in the future.
• Fortress Biotech controls a voting majority of the company's common stock, which could be detrimental to other shareholders.

Future Outlook

The company anticipates a productive second half of 2024 with additional business progress and continued financial performance, particularly with the upcoming DFD-29 PDUFA date. They remain on track to deliver on their 2024 financial guidance.

Management Comments

• We continued to execute on our business plan in the second quarter, delivering $14.9 million in total net product revenue and positive Adjusted EBITDA.
• We are pleased with these results, particularly given our strategic decision to reduce the Company's expense base in 2023.
• We believe that the business is now sufficiently right-sized to support our core dermatology franchise and effectively launch DFD-29.
• We're looking forward to the DFD-29 PDUFA date and anticipate a productive second half of 2024 with additional business progress and continued financial performance.
• Importantly, we grew revenue 14% sequentially from the first quarter of this year as we remain on track to deliver on our 2024 financial guidance.

Industry Context

This announcement comes as Journey Medical focuses on its core dermatology franchise and the potential launch of DFD-29, a novel treatment for rosacea. The company is navigating a competitive landscape with generic competition and is working to optimize its cost structure. The successful approval of DFD-29 could significantly impact its market position.

Comparison to Industry Standards

• Journey Medical's sequential revenue growth of 14% is a positive sign, indicating a potential turnaround after a year-over-year decline of 12%.
• The company's move to reduce expenses and achieve positive adjusted EBITDA is a common strategy for smaller pharmaceutical companies aiming for profitability.
• The focus on a specific therapeutic area (dermatology) and a novel product (DFD-29) is a typical approach for companies in this sector.
• Compared to larger pharmaceutical companies, Journey Medical is more vulnerable to generic competition and requires successful product launches to drive growth.
• The company's cash position of $23.9 million is relatively modest, highlighting the need for careful financial management and potential future capital raises.
• Companies like Galderma and Almirall, which also focus on dermatology, serve as benchmarks for Journey Medical in terms of product development and commercialization strategies.

Management Changes

Related Party Transactions

• The company has a 'Due to related party' liability of $260,000 as of June 30, 2024.

Stakeholder Impact

• Shareholders may view the sequential revenue growth and positive adjusted EBITDA as positive developments.
• Employees may be impacted by the company's cost reduction efforts.
• Customers may benefit from the potential launch of DFD-29.
• Suppliers and creditors may be impacted by the company's financial performance.

Next Steps

• The company will hold a conference call to discuss the financial results and provide a business update.
• The company is awaiting the FDA's decision on the DFD-29 NDA with a PDUFA goal date of November 4, 2024.
• The company will continue to focus on its core dermatology franchise and the potential launch of DFD-29.

Key Dates

Keywords

dermatology, pharmaceutical, DFD-29, rosacea, FDA, revenue, EBITDA, clinical trials, prescription drugs, financial results